Clinical Trial Update: A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body [Phase 1]

View source ↗

Summary

Phase 1 study of galunisertib (LY2157299) in pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Galunisertib (galunisertib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Pancreatic Neoplasms | Phase 1 | Status: COMPLETED